All Stories

  1. Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension

    Article • Journal of Pharmacology and Experimental Therapeutics, January 2019, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Marc Iglarz

  2. The Endothelin Receptor Antagonist Macitentan Improves Isosorbide-5-Mononitrate (ISMN) and Isosorbide Dinitrate (ISDN) Induced Endothelial Dysfunction, Oxidative Stress, and Vascular Inflammation

    Article • Oxidative Medicine and Cellular Longevity, December 2018, Hindawi Publishing Corporation

    Professor Thomas Munzel or Muenzel, Dr Marc Iglarz

  3. Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential

    Article • Journal of Pharmacology and Experimental Therapeutics, May 2017, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Marc Iglarz

  4. The Discovery of Macitentan—A Standard Medicinal Chemistry Program?

    Article • January 2017, Elsevier

    Dr Marc Iglarz

  5. Absence of ETA receptors on podocytes is not antialbuminuric in diabetic mice

    Article • Life Sciences, December 2013, Elsevier

    Dr Nicolas Vignon-Zellweger, Dr Marc Iglarz

  6. At the heart of tissue: endothelin system and end-organ damage

    Article • Clinical Science, December 2010, Portland Press Ltd.

    Dr Marc Iglarz

  7. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP

    Article • Journal of Hypertension, February 2008, Wolters Kluwer Health

    Dr Marc Iglarz

  8. Mechanisms of ET-1-induced Endothelial Dysfunction

    Article • Journal of Cardiovascular Pharmacology, December 2007, Wolters Kluwer Health

    Dr Marc Iglarz

  9. Position of Src tyrosine kinases in the interaction between angiotensin II and endothelin in in vivo vascular protein synthesis

    Article • Journal of Hypertension, February 2005, Wolters Kluwer Health

    Dr Marc Iglarz

  10. Role of endothelin-1 in hypertension

    Article • Current Hypertension Reports, April 2003, Springer Science + Business Media

    Dr Marc Iglarz

  11. Genetic determinants of vascular reactivity

    Article • Current Hypertension Reports, February 2002, Springer Science + Business Media

    Dr Marc Iglarz

  12. Prolonged Blockade of Endothelin ETA Receptors Decreases Vascular Reactivity in the Aorta of Spontaneously Hypertensive Rats In Vitro

    Article • Journal of Cardiovascular Pharmacology, September 1999, Wolters Kluwer Health

    Dr Marc Iglarz

  13. Chronic endothelin-1-induced changes in vascular reactivity in rat resistance arteries and aorta

    Article • European Journal of Pharmacology, October 1998, Elsevier

    Dr Marc Iglarz

  14. Chronic blockade of endothelin ETA receptors improves flow dependent dilation in resistance arteries of hypertensive rats

    Article • Cardiovascular Research, September 1998, European Society of Cardiology

    Dr Marc Iglarz